Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have histologically proven diagnosis of Non-Squamous NSCLC. NSCLC histologies that will be included in this trial will be adenocarcinoma, large cell carcinoma and adeno-squamous carcinoma. Patients with bronchioloalveolar carcinoma (BAC) will be also included in this trial.~* Patients must be 70 years of age or older.~* Patient must have either stage IIIB disease with malignant pleural effusion or stage IV disease. All patients must have measurable disease. Evaluable disease will be separately outlined and elucidated.~* Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1.~* Patient must have adequate renal function with a serum creatinine level of less than 1.5mg/dl and patient should have a calculated creatinine clearance of more than 45ml/min.~* Patient must have adequate hepatic function with a serum bilirubin level of less that 3mg/dl, and an alkaline phosphatase, Alanine Amino Transferase (ALT) and Aspartate Amino Transferase (AST) of less than three times the upper limit of normal~* Patient must also have evidence of adequate bone marrow function with an absolute neutrophil count of more than 1, 500 cells per deciliter and a platelet count of more than 100,000 per deciliter.~* Patients must be more than 28 days since prior open biopsy; more than 7 days since prior fine-needle aspiration; more than 7 days since prior core biopsy; more than 28 days since prior surgery.~* Patients must be able to take dexamethasone, folic acid and vitamin B-12 supplementation.~* All patients must sign informed consent that will detail the investigational nature of the study in accordance with the institutional and federal guidelines.~Exclusion Criteria:~* Lung carcinoma of squamous cell histology or any histology in close proximity to a major vessel, with or without cavitation.~* Patients with hypercalcemia (corrected calcium of more than 11 mg/dl) will be excluded.~* Patients with history of hemoptysis, hematemesis, coagulopathy or thrombosis will be excluded.~* Patients requiring anticoagulation for any reason will be excluded.~* Patients who recently have an acute infection.~* History of palliative radiation therapy within 2 weeks.~* Blood pressure of \>150/100 Millimeter Mercury(mmHg).~* Currently ongoing unstable angina.~* New York Heart Association (NYHA) Grade II or greater congestive heart failure.~* History of myocardial infarction within 6 months.~* History of stroke within 6 months.~* Clinically significant peripheral vascular disease.~* Presence of central nervous system or brain metastases.~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study.~* Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0.~* Pregnant (positive pregnancy test) or lactating.~* Urine calculated creatinine clearance of less than 45ml/minute and a urinary protein. Creatinine ratio of more than 1.~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1.~* Serious, non-healing wound, ulcer, or bone fracture.~* Inability to comply with study and/or follow-up procedures.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab, Erlotinib, Pemetrexed (Type: EXPERIMENTAL): Single Arm Phase II trial in elderly patients with advanced stage Non-Squamous Non-Small Cell Lung Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).